PlosOne January 20, 2021
https://doi.org/10.1371/journal.pone.0241899
Antibiotic fixed dose combinations (FDCs) can have clinical advantages such as improving effectiveness and adherence to therapy. However, high use of potentially inappropriate FDCs has been reported, with implications for antim...icrobial resistance (AMR) and toxicity.
more
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
htb supplement: 2018 Vol 19:(1)
New drugs in development
July 2018
www.i-Base.info
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development
Three Years After Enactment of the Drug Quality and Security Act
TB treatment for children is fundamentally the same as for adults, with a combination of TB drugs needing to be taken for a number of months. TB treatment for children consists of an intensive phase followed by a continuation phase. The purpose of the intensive phase is to rapidly eliminate the majo...rity of the TB bacteria, and this phase uses a greater number of TB drugs than the continuation phase whose aim is to eradicate any remaining dormant bacteria.
Accessed Nov. 07. 2017
more
Lessons from the STEP-TB Project.
Accessed November 2017.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
Research Article
PLOS ONE | DOI:10.1371/journal.pone.0164619 October 13, 2016
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Downloaded from https://aidsinfo.nih.gov/guidelines on 10/19/2019
Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office
of AIDS Research Advisory Council (OARAC)